DEFR14A: Atara Biotherapeutics Clarifies Voting Standards and Corrects Error in Proxy Statement

Atara Biotherapeutics issues a supplement to its proxy statement to clarify voting standards, the treatment of broker non-votes, and correct a scrivener's error for the upcoming 2024 Annual Meeting of Stockholders.

Summary

• Atara Biotherapeutics has released a supplement to its definitive proxy statement filed on April 26, 2024.
• The supplement clarifies voting standards and the treatment of broker non-votes for Proposals 1, 2, 4, 5 and 6.
• It also corrects a scrivener's error in the original proxy statement.
• The supplement emphasizes that broker non-votes will not affect the determination of whether Proposals 1, 2, 4, 5 and 6 are approved.
• The company urges stockholders to provide voting instructions to their brokers to ensure their shares are represented in the vote.
• The supplement clarifies the vote required for approval of Proposals 4, 5, 6, and 7, stating that it requires 'For votes from the holders of a majority of shares present in person, present by remote communication, if applicable, or represented by proxy and entitled to vote on the matter'.
• The effect of abstentions is 'Against' for Proposals 4, 5, 6 and 7.
• For Proposal 7, brokers have discretion to vote.
• The supplement is dated May 10, 2024, and pertains to the Annual Meeting of Stockholders scheduled for June 10, 2024.
• Stockholders who have already submitted their proxy do not need to take further action unless they wish to change their vote.

Sentiment

Score: 7

Explanation: The document is a neutral clarification of voting procedures, indicating standard corporate governance practices. There is no indication of positive or negative financial performance, so the sentiment is moderately positive due to the proactive communication.

Positives

• The company is proactively clarifying potential ambiguities in the proxy statement.
• Stockholders are given clear instructions on how to ensure their votes are counted.

Industry Context

Proxy statements are standard documents for publicly traded companies, and this supplement addresses specific voting matters relevant to Atara Biotherapeutics' upcoming annual meeting.

Stakeholder Impact

• Shareholders are provided with clarified voting information.
• The supplement ensures that shareholder votes are accurately represented.

Next Steps

• Stockholders should review the supplement and the original proxy statement before voting.
• Stockholders should provide voting instructions to their brokers.

Key Dates

Keywords

proxy statement, Atara Biotherapeutics, voting standards, broker non-votes, annual meeting, equity incentive plan, reverse stock split, stockholders